CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
Alisertib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02560025
NCT02560025Phase 2Completed
CompareCT.gov

A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia

Massachusetts General Hospital·interventional·Posted Sep 25, 2015·Updated May 5, 2020

In Brief

A Phase 2 clinical trial evaluating Alisertib, Cytarabine, and 2 other interventions for Acute Myeloid Leukemia. Completed, enrolled 42 participants across 2 sites.

Detailed Summary

This research study is studying a targeted therapy (a form of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells) as a possible treatment for high-risk acute myeloid leukemia. The names of the study interventions involved in this study are: * Alisertib / MLN8237 * Cytarabine / Cytosine Arabinoside * Idarubicin / Idarubicin hydrochloride * Daunorubicin (Can be used in place of idarubicin)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesUnited States
CollaboratorsTakeda

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 25, 2015
Enrollment StartDec 1, 2015
Primary CompletionOct 1, 2017
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.8 years ago

Interventions

Alisertibdrug

Cytarabinedrug

Idarubicindrug

Daunorubicindrug

Can be used in place of idarubicin